Journal of Addiction Medicine

Article	Citations
A Naturalistic Study of Individuals Involved in the Justice System Who Experienced Both Formulations of Extended-release Buprenorphine	92
Oral Health Risks of Transmucosal Buprenorphine: Commentary on Tuan et al. and Zheng et al.	67
Methamphetamine Use in Psychiatric Emergency Services and Among Asian American and Pacific Islander Populations	67
Characteristics of Ongoing Clinical Trials for Cocaine Use Disorder Registered on Global Clinical Trial Databases	55
Neonatal Outcomes after Medications for Opioid Use Disorder during Pregnancy in a State Women’s Prison Facility, 2016–2019	55
Generative Artificial Intelligence Tools in Medicine Will Amplify Stigmatizing Language	52
Differences in Self-identification of Opioid Overdose Risk and Naloxone Perceptions Between Therapeutic and Nontherapeutic Opioid Populations	42
GLP-1 RA Medication Associations With Hazardous Alcohol Drinking Reductions in Patients With Overweight or Obesity: A Prospective Observational Study	41
Patient Satisfaction With Standard Methadone and Flexible Buprenorphine/Naloxone Models of Care: Results From a Pragmatic Randomized Controlled Clinical Trial	38
Implantable Cardioverter Defibrillator Placement to Permit Ongoing Methadone Treatment Despite QT Prolongation and Torsades de Pointes: A Case Report	38
Synthetic Cathinone–Induced Myocarditis and Psychosis: A Case Report	38
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder	35
Managing Benzodiazepine Withdrawal—The Emperor’s New Clothes	34
Treatment of Kratom Use Disorder With Methadone in an Opioid Treatment Program	32
Initiatives to Support the Transition of Patients With Substance Use Disorders From Acute Care to Community-based Services Among a National Sample of Nonprofit Hospitals	30
A Brief Intervention on Alcohol Use Disorder Is Associated With Treatment Access for Inpatients With Alcohol-associated Liver Disease	29
The Pharmacological Management of Ketamine Use Disorder: A Systematic Review	26
Responses to a “Typical” Morning Dose of Kratom in People Who Use Kratom Regularly: A Direct-Observation Study	25
Perinatal Substance Use-Related Content at Major Addiction Scientific Conferences: An Analysis of Oral Presentation Sessions	24
Provider Perceptions Toward Extended-Release Buprenorphine for Treatment of Opioid Use Disorder	23
Complicating Factors Surrounding Concurrent Use of Kratom and a Novel 7-hydroxymitragynine Product Among a Participant Enrolled in a Kratom Clinical Trial	23
Adolescent Tobacco/Nicotine Use and the Potential Role of Contingency Management-based Interventions	23
Clinical and Demographic Characteristics of Hospitalized Patients With Xylazine-related Wounds	21
Associations between Patient Experience and Addiction Treatment Facility Services: Results of the Addiction Treatment Locator, Assessment, and Standards Surveys	21
Outcomes in Subsequent Pregnancies of Individuals With Opioid Use Disorder Treated in Multidisciplinary Clinic in Prior Pregnancy	20

Identifying Areas to Improve Care and Support Parent-Child Relationships From the Perspective of Pregnant and Parenting People in Recovery	20
Approaches for Managing Benzodiazepine Dependence Arising From Use of the Adulterated Opioid Supply: A Delphi Technique	19
Drive Time to Addiction Treatment Facilities Providing Contingency Management across Rural and Urban Census Tracts in 6 US States	18
Stigmatizing Language in Substance Use-related International Classification of Diseases Codes	18
Low-dose Buprenorphine Initiation in Pregnancy: A Systematic Review	18
Subcutaneous Extended-release Buprenorphine Depot Misdiagnosed as an Abscess Resulting in Incision and Drainage and Disruption of Opioid Use Disorder Treatment	18
Rating the Quality and Consistency of Local Opioid Settlement Expenditure Data	17
Testing and Case Rates of Gonorrhea, Chlamydia, Syphilis, and HIV among People with Substance Use Disorders in the Veterans Health Administration	17
Assessing Childhood Maltreatment Exposure in Patients Without and With a Diagnosis of Substance Use Disorder	16
Use of Cannabinoids by People Who Consume Kratom in the United States	16
A Peer Recovery Coach Intervention for Hospitalized Patients with Opioid Use Disorder: A Pilot Randomized Controlled Trial	16
Dosing and Safety of Methadone Initiation in the Setting of Fentanyl: A Systematic Review	16
High Primary COVID-19 Vaccine Series Completion by People Who Inject Drugs When Colocating Services at a Syringe Services Van	16
Gains in Employment Status Are Associated With Lower Methamphetamine Use Frequency at Outpatient Specialty Treatment Discharge	16
Trauma Prevalence and Its Association With Health-related Quality of Life in Pregnant Persons With Opioid Use Disorder	16
Feasibility of Emergency Department–based Fentanyl Test Strip Distribution	15
Individuals Dispensed Buprenorphine in the United States Before and After Federal Policy Changes Aimed at Increasing Access	15
Xylazine Use Among People Who Inject Drugs, Philadelphia 2022	15
Implementation of Telemedicine Delivery of Medications for Opioid Use Disorder in Pennsylvania Treatment Programs During COVID-19	15
Adapting Contingency Management for Hospitalized Patients with Stimulant Use Disorder	15
Fentanyl Test Strips for Harm Reduction: A Scoping Review	13
Systematic Review of Obstetric and Child Outcomes of Prenatal Exposure to Inhalants in the Context of a Use Disorder	12
Integrative Analysis of Proteome-wide Association Studies and Functional Enrichment Analysis to Identify Genes and Chemicals Associated with Alcohol Dependence	12
Online Narcotics Anonymous: An Option for Addressing Methamphetamine Use Disorder	12
Public Xylazine Awareness and Support for Policies and Initiatives to Address the Xylazine Threat Among US Adults	12
Climate Change and the Opioid Epidemic	12
Trends in Buprenorphine and Methadone Initiation for Opioid Use Disorder Among Patients Using Fentanyl: A Mixed-methods Analysis From an Inpatient Addiction Consult Service	12
Opioid Settlements: The Role for Addiction Medicine in Guiding Effective Spending	12
Current State of Perioperative Buprenorphine Management—A National Provider Survey	12
A Hospital-based Managed Alcohol Program in a Canadian Setting	12
The Association Between Perceived Injustice and Opioid Craving in Patients With Chronic Pain: The Mediating Role of Daily Pain Intensity, Negative Affect, and Catastrophizing	12
Exploring Family Planning Perspectives Among Men Receiving Medications for Opioid Use Disorder: Implications for Service Development	11
Letter in Reply	11
Medical Detoxification for Nonopioid Substances Is Associated With Lower Likelihood of Subsequent Linkage to Substance Use Disorder Treatment	11
Estimating the Prevalence of Using Suspected Counterfeit Medications in the General Population	11
The Effect of Dehydroepiandrosterone Administration during Rehabilitation on White Matter Integrity Among Individuals With Polysubstance Use Disorder	11
Response to: “Prevalence of Kratom Use Disorder among Kratom Consumers”	11
Investigating Healthcare Provider Bias Toward Patients Who Use Drugs Using a Survey-based Implicit Association Test: Pilot Study	10
Clinical Presentations and Treatment of Phenibut Toxicity and Withdrawal: A Systematic Literature Review	10
Xylazine Test Strip Use Among People Who Use Drugs in New York State	10
Evidence of Designer Benzodiazepine Use in Routine Healthcare Urine Drug Specimens	10
48-hour Induction of Transdermal Buprenorphine to Sublingual Buprenorphine/Naloxone: The IPPAS Method	10
Retention and Overdose Risk among Patients Receiving Substance Use Disorder Treatment, Mental Health Care and Peer Recovery Support: A Longitudinal Analysis	10
Discordance Between Self-reported and Biologically Tested Exposure to Fentanyl Among People at Risk of Opioid Overdose	10
ASAM/AAAP Clinical Practice Guideline (CPG) for Stimulant Use Disorder (StUD) Management: Commentary on Research Priorities	10
Integration of Substance Use Disorder Services in Veterans Affairs Primary Care Clinics Serving Homeless Women	10
Too Many Pills, Too Little Attention: Emphasizing Psychotropic Polypharmacy in the Overdose Conversation	10
Insurance-related Risk Factors for Leaving Against Medical Advice after Opioid Overdose: A Cross-sectional Study Using Electronic Health Records	10
The Use of Pattern Recognition to Augment Traditional Monitoring in the Prevention of Opioid Overdose Harm	10
The Difficulties in Finding the Relevant Associations Between Internet Gaming Disorder (IGD) and the Incidence of Suicide-Related Ideation and Behaviors in College Students	10

Evidence of “Repeated Admission Bias” Among Those Who Use Injection Drugs Across 2 Decades of US Treatment Admissions: 2000–2020	10
Kratom Use Among Pregnant and Lactating Individuals With Substance Use Disorder	9
Addiction Services for Veterans: Opportunities in Acute Care	9
The Use of a Single Dose of Phenobarbital for Inpatient Management of Benzodiazepine Withdrawal: A Case Report	9
Increasing Initiation of Medications for Opioid Use Disorder Through Recovery Coaches: The Role of Implementation Setting	9
A Scoping Review of Youth Overdose Prevention Interventions	9
Missed Opportunities: Substance Use Hotline Operator Uncertainty of State Buprenorphine Prescribing via Telemedicine	9
Response to "Two Clinical Insights on Methamphetamine Withdrawal at a Safety-net Hospital"	9
Chronic Pain Associated Alcohol Use Disorder Among Participants in a Small Clinical Trial	9
Co-use of Methamphetamine Is Associated With Lower Rates of Linkage to Outpatient Treatment for Hospitalized Patients Who Initiate Buprenorphine	9
Perceptions of Overdose Response Hotlines and Phone Application Services Among Women and Gender-diverse Individuals Who Use Drugs in Canada: A Qualitative Study	9
Secondary Analysis of Agreement Between Negative Timeline Follow Back Report and Negative Urine Toxicology in a Large Trial of Individuals with Opioid Use Disorder	9
The Shifting Landscape of a Fentanyl Adulterant: Moving From Xylazine to Medetomidine	9
Concerns for Discharge of Persons Who Inject Drugs Home With Central Venous Catheters: A Letter to the Editor	9
Reply to: “Co-use of Methamphetamine Is Associated With Lower Rates of Linkage to Outpatient Treatment for Hospitalized Patients Who Initiate Buprenorphine”	9
Barriers and Facilitators to Accessing Opioid Agonist Therapy for Street-involved Adolescents and Young Adults in Vancouver	9
Three-year Retention Rates With Office-based Treatment of Buprenorphine for Opioid Use Disorder in a Private Family Medicine Practice	9
N-acetylcysteine Efficacy on Cocaine Base Paste Use Disorder: A Randomized Double-blind Placebo-controlled Clinical Trial	9
Aripiprazole Is Not Effective for Abstinence or Decreased Use in Alcohol and Stimulant Use Disorders in Patients Without Psychiatric Comorbidities: A Systematic Review	9
Longitudinal Patterns of Dental Health Care Utilization 18 Months Before and 36 Months After Initiation of Index Medications for Opioid Use Disorder	9
Wound Care Capacity of the Addiction Workforce in the Setting of Xylazine	9
Z-Drug Use and Benzodiazepine Use and Misuse Among LGB Populations: The Role of Psychological Distress	9
Sociodemographic and Health Factors of the Alcohol Treatment-seeking Population in New South Wales, Australia	9
Simultaneous Management of Alcohol Use Disorder and Liver Disease: A Systematic Review and Meta-analysis	9
Using Machine Learning to Predict Treatment Adherence in Patients on Medication for Opioid Use Disorder	8
Examining Racial/Ethnic and Income Disparities on Tobacco Product Use Among US Adults Within Wave 5 of the PATH Study	8
48-hour Induction of Transdermal Buprenorphine to Extended-release Buprenorphine	8
Increased Risks of Major Cardiac Adverse Events in Stimulant Use Disorder as Compared With Other Substance Use Disorders: A Propensity-score Matching Cohort Study	8
Heterogeneity in Prescription Opioid Misuse Motives by Age in Adolescents and Young Adults in the United States	8
Response to: “Chronic Pain Associated Alcohol Use Disorder Among Participants in a Small Clinical Trial”	8
Satisfaction With Opioid Agonist Treatment: The Compelling Need for Multidimensional, Patient-centered, Patient-reported Experience Measures	8
Artificial Intelligence and Stigma in Addiction Research: Insights From the HEALing Communities Study Coalition Meetings	8
Direct Induction of Buprenorphine Extended-Release: A Case Report	8
Validating the Waterpipe Addiction, Craving, and Anticipation Scale: An Exploratory Factor Analysis	8
Prevalence of Kratom Use Disorder Among Kratom Consumers	8
Cannabis and Cannabinoids for Treating Pain: What Are the Data?	8
Implementation of Specialty Tobacco Use Disorder Services in a Community Health Setting: Support for Enhanced Prescription Practices	8
Examining the Primary Care Experience of Patients With Opioid Use Disorder: A Qualitative Study	8
Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation	8
Testing the Efficacy of an Adaptive Approach to Delivering Psychosocial Interventions in Office-based Buprenorphine Treatment	8
Identifying Factors Associated With Intentional and Unintentional Fentanyl Use Among People Who Use Drugs in New York City	8
Anhedonia and Substance Use Disorders by Type, Severity, and With Mental Health Disorders	8
Readmissions Among Patients With Surgically Managed Drug Use Associated-Infective Endocarditis Before and After the Implementation of an Addiction Consult Team: A Retrospective, Observational Analysis	8
Opioid Use Disorder Screening Practices in US Jails	8
A Critical Appraisal on the Alleged Carcinogenic Potential of Sublingual Buprenorphine	7
Patterns of Substance Use During Early Pregnancy and Associations With Behavioral Health Characteristics	7
Nonopioid Substance Use among Patients Who Recently Initiated Office-based Buprenorphine Treatment	7
False-Positive Phosphatidylethanol Results Due to Blood Transfusion and Implications in the Process of Liver Transplantation Selection	7
Response to Martins et al.	7
Health Care Service Presence, Social Vulnerability, and Opioid Overdose Rate Acceleration: A United States, County-level Analysis, 2020–2022	7
Identifying Barriers to Buprenorphine Treatment for Patients with Opioid Use Disorder Among Anesthesiologists and Pain Practitioners: A Survey Study	7
Emergency Department Presentations Related to the Abuse of Illicit and Prescription Opioids Through a European Sentinel-centres–Based Registry	7
Injection Drug Use and Healthcare Utilization in Patients Newly Diagnosed With HIV	7
Feasibility of a Brief Intervention to Decrease Harmful Alcohol Use Among Methadone Maintenance Treatment Clients in Shanghai: A Randomized Controlled Trial	7
Fentanyl Absorption, Distribution, Metabolism, and Excretion: Narrative Review and Clinical Significance Related to Illicitly Manufactured Fentanyl	7
Medication Initiation, Patient-directed Discharges, and Hospital Readmissions Before and After Implementing Guidelines for Opioid Withdrawal Management	7
Challenges of Drug Testing in Addiction Treatment	7
The Impact of Frequency of Cannabis Use on Hypertensive Disorders During Pregnancy	7
Response to the Federation of State Physician Health Program's Commentary	7
Regular Kratom (Mitragyna speciosa Korth.) Use and Its Association With Endoplasmic Reticulum Stress Response	7
Community-based Care Coordination and Treatment Retention in Opioid Use Disorder	7
Medications for Alcohol Use Disorder Among Birthing People With an Alcohol-related Diagnosis	7
Development and Validation of a High-sensitivity Rapid Xylazine Dipstick for Clinical Urine Testing	7
Disruption of Opioid Treatment Program Services Due to an Extreme Weather Event: An Example of Climate Change Effects on the Health of Persons Who Use Drugs	7
Supervised Disulfiram Should Be Considered First-line Treatment for Alcohol Use Disorder	7
Predictors of the Rate of Illicit Fentanyl Metabolism in a Cohort of Pregnant Individuals	7
“Just Be There”: Desired Partner Behaviors Among Pregnant People Living With Opioid Use Disorder, a Qualitative Study	7
Disparities in Buprenorphine Administration for Opioid Use Disorder in the Emergency Department	6
Effectiveness and Safety of Varenicline for Smoking Cessation: An Overview and Meta-analysis	6
Response to: “Clinician Perspectives on Barriers and Facilitators to Providing Medications for Opioid Use Disorder for Adolescents”	6
Xylazine Exposure and Association With Early Physiological and Withdrawal Symptoms in People With Opioid Use Disorder	6
A Critique of Phenobarbital Tapers With Buprenorphine or Methadone Initiations	6
Does Labetalol Trigger False Positive Drug Testing Results?	6
The First 100 Days: The Trump Administration and Changes to Addiction Policy	6
Naloxone Prescribing and Naloxone Administration in Response to Overdose Events Among Women With Opioid Use Disorder During Pregnancy and Postpartum Period – MAT-LINK, Seven Clinical Sites, 2014–2021	6
Safety and Efficacy of Rapid Methadone Titration for Opioid Use Disorder in an Inpatient Setting: A Retrospective Cohort Study	6
Predictive Models to Assess Risk of Persistent Opioid Use, Opioid Use Disorder, and Overdose	6
Ibogaine for Opioid Use Disorder: An Unrecognized Risk	6
A Retrospective Cohort Study of Oral Antimicrobial Therapy Offers in Hospitalized People Who Inject Drugs Who Elect for Self-directed Discharge	6
The Impact of High-Potency Synthetic Opioids on Pharmacotherapies for Opioid Use Disorder: A Scoping Review	6

Opioid Use Disorder Among the Economically Disadvantaged in the Rural South	6
Expert Views on State Policies to Improve Engagement and Retention in Treatment for Opioid Use Disorder: A Qualitative Analysis of an Online Modified Delphi Process	6
Outpatient Direct Initiation of Injectable Buprenorphine in a Harm Reduction Agency and Primary Care Clinic: A Retrospective Case Series	6
Parosmia Is Positively Associated With Problematic Drinking, as Is Phantosmia With Depressive Symptoms	6
Buprenorphine-naloxone Versus Buprenorphine for Treatment of Opioid Use Disorder in Pregnancy	6
Feasibility of an Inpatient Split-Dose Rapid Methadone Induction Protocol for Pregnant Individuals	6
Gabapentin Use During Pregnancy and Lactation With and Without Concurrent Opioid Exposure: Considerations and Future Directions	6
The American Society of Addiction Medicine Clinical Practice Guideline Development Methodology	6
The Concept of Treatment-Refractory Addiction: Implications for Addiction Treatment Systems and Research	6
Participant Experiences of a Quit Smoking Attempt Through Either Nicotine Replacement Therapy (NRT) Methods or the Use of an E-cigarette	6
A Brief Screening and Assessment Tool for Opioid Use in Adults: Results from a Validation Study of the Tobacco, Alcohol, Prescription Medication, and Other Substances Tool	6
Predictors of Treatment Completion in an Inpatient Substance Use Treatment Service in India	6
Quetiapine: A Novel Additive to the Illicit Heroin Supply in Los Angeles	6
Use of Practices to Reduce of Sudden Unexpected Infant Death Among Caregivers of Opioid Exposed Newborns	6
Changes in Rates of Hospitalizations due to Cannabis Harms in Ontario, Canada Before the Legalization of Nonmedical Cannabis: Retrospective Population-level Study Between 2003 and 2017	6
Explaining Racial-ethnic Disparities in the Receipt of Medication for Opioid Use Disorder during Pregnancy	5
Universal Postpartum Naloxone Provision: A Harm Reduction Quality Improvement Project	5
Risk of Cannabis Use Disorder in Chronic Pain: Longitudinal Links to Pain Outcomes	5
Privacy, Care-seeking, and Stigma: A Qualitative Investigation of Patient Perspectives on Sharing Substance Use Disorder Treatment Records	5
Naloxone Use During Pregnancy—Data From 26 US Jurisdictions, 2019–2020	5
“The Sky Didn’t Fall”: Patient and Clinician Experiences With Increased Buprenorphine Prescription Lengths During Pandemic-related Telehealth Expansion	5
Response to: Buprenorphine Initiation, Patient Autonomy, and Informed Consent	5
The Prognostic Role of DSM-5 Alcohol Use Disorder Severity and Age of Onset in Treatment Outcome Among Adults Aged 60+	5
Privacy and Digital Health: Causes for Concern and a Way Forward	5
Exploring Preferences for Communication and Care Among Hospitalized Patients With Opioid Use Disorder: A Qualitative Descriptive Study	5
Prescribing Psychostimulants for the Treatment of Stimulant Use Disorder: Navigating the Federal Legal Landscape	5
Self-reported Xylazine Experiences: A Mixed-methods Study of Reddit Subscribers	5
Circumstances Around Cigarette Use after Enforced Abstinence From Smoking in an American Prison	5
Xylazine-associated Wounds: Clinical Experience From a Low-barrier Wound Care Clinic in Philadelphia	5
Opioid Agonist Therapy for Fentanyl-Related Opioid Use Disorder: A Systematic Review	5
Racial Disparities in Urine Toxicology Screening Among Pregnant People Admitted to Labor and Delivery	5
An Integrated Care Model for Pregnant and Postpartum Individuals Receiving Medication for Opioid Use Disorder	5
2024 ASAM Annual Conference Poster Abstracts	5
Microdose Induction of Buprenorphine in a Patient Using Tianeptine	5
Prevalence and Correlates of Past-year Kratom Use Among US Adults: Findings From the 2021–2023 National Survey on Drug Use and Health	5
Reductions in World Health Organization Risk Drinking Level Are Associated With Reductions in Alcohol Use Disorder Diagnosis and Criteria: Evidence From an Alcohol Pharmacotherapy Trial	5
Precipitated Opioid Withdrawal Treated With Ketamine in a Hospitalized Patient: A Case Report	5
Community Pharmacists’ Knowledge and Perceptions of Buprenorphine for Patients with Opioid Use Disorder	5
Predictors of Risky Sexual Behaviors Among Female Adolescents and Young Adults Seeking Withdrawal Management Treatment: A Lifestyle-routine Activities Theory Approach	5
Transition to Extended-release Buprenorphine Injectable Within Seven Days for Opioid Use Disorder Treatment: A Scoping Narrative	5
Outpatient Rapid Titration of Slow Release Oral Morphine for the Treatment of Opioid Use Disorder in a Canadian Setting: A Case Series	5
Isolated Kratom Use Disorder Treated With Extended-Release Buprenorphine Taper	4
Description of Physician Champion Efforts to Expand Buprenorphine Treatment in Primary Care and Explore a Quality Implementation Measure of Success: Buprenorphine as a Percentage of All Opioids Prescr	4
Financial Well-being and Impact on Alcohol and Mental Health Outcomes During the COVID-19 Pandemic	4
Effectiveness of and Access to Medications for Opioid Use Disorder for Adolescents and Young Adults: A Scoping Review	4
Early Long-Acting Buprenorphine for Opioid Use Disorder in the Setting of Acute Pain	4
Perspectives of Patients Receiving Telemedicine Services for Opioid Use Disorder Treatment: A Qualitative Analysis of User Experiences	4
Pandemics Interlaced: The Impact of the COVID-19 Pandemic on the Wellbeing of Sober Living Home Residents	4
Integrating Ambulatory Addiction Consultation Service Into a Community Mental Health Center	4
Medication for Opioid Use Disorder for Hospitalized Patients at Six New York City Public Hospitals With an Addiction Consult Service	4
An Open-label Pilot Study of NicoBloc as a Novel Smoking Cessation Intervention	4
Facilitating Integrated Perinatal Care for Families Affected by Substance Use	4
Association Between Smoking Abstinence and Depression and Anxiety Symptoms After Hospital Discharge: The Helping HAND 4 Trial	4
Response to Avoiding NICU Transfer for Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS): A Quality Improvement Initiative to Manage NOWS on the Mother-baby Unit	4
Trajectories of Opioid Misuse and Opioid Use Disorder Among Adults With Chronic Pain and HIV: An Observational Study	4
Sex-specific Trends in Methamphetamine Use in the United States, 2002–2022	4
Rectal Methamphetamine Use, a Likely Cause of Sigmoid Colon Perforation: A Case Report	4
Dutasteride as a Treatment to Support Reduced Drinking: A Randomized Placebo-Controlled Trial	4
Revisiting the X:BOT Naltrexone Clinical Trial Using a Comprehensive Survival Analysis	4
Standard Versus Rapid Inpatient Methadone Titration for Pregnant Patients With Opioid Use Disorder: A Retrospective Cohort Study	4
Benzodiazepine Tapering: A Marathon, Not a Sprint	4
Low-dose Initiation of Buprenorphine in Hospitalized Patients Using Buccal Buprenorphine: A Case Series	4
An Attendance-based Contingency Management Pilot Program for Veterans Experiencing Homelessness With Stimulant-associated Cardiomyopathy in Primary Care	4
Factors Associated With the Presence of Co-occurring Pain and Substance Use Disorder Programs in Substance Use Treatment Facilities	4
Kava-potentiated Withdrawal in Persons Using Multiple Substances: A Case Series of Kava and Kratom Co-ingestion	4
Expanding Medical Education to Include Substance Use Disorders During Pregnancy and Postpartum: Preliminary Effectiveness of a Pilot Curriculum for Medical Students	4
Effect of COVID-19 on the Long-term Cardiovascular Outcomes among Patients with Alcohol Use Disorder: A Retrospective Cohort Study Including 45,842 Patients	4
A Quantitative Examination of Illness Models Among People With Opioid Use Disorder Receiving Methadone Treatment	4
Implementation of a Naloxone Best Practice Advisory Into an Electronic Health Record	4
Evaluation and Management of Buprenorphine Extended-Release Injection Thrombophlebitis: A Case Report	4
Homelessness and Treatment Outcomes Among Black Adults With Opioid Use Disorder: A Secondary Analysis of X:BOT	4
The Use of Extended-Release Buprenorphine in the Treatment of Adolescent Opioid Use Disorder: A Case Series	4
Impact of X-Waiver Elimination on Post–Hospital Discharge Buprenorphine Prescribing: An Interrupted Time Series Analysis	4
Xylazine Positivity in Opioid-positive Drug Screens on an Inpatient Labor Unit	4
Differential Gateways, Facilitators, and Barriers to Substance Use Disorder Treatment for Pregnant Women and Mothers: A Scoping Systematic Review	4
Global, Regional, and National Burdens Attributable to Drug Use Across 204 Countries and Territories Between 1990 and 2021: The Global Burden of Disease Study 2021	4
Precipitated Withdrawal following Emergency Department-initiated Buprenorphine: A Retrospective Study	4
Impact of Cocaine Use Disorder History on Receipt of Guideline-indicated Medications and Therapies Following ST-elevated Myocardial Infarction	4
Age-related Psychometric Dimensionality Using the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition Opioid Use Disorder Diagnostic Criteria	4
Exploring Opioid Use Disorder Outcomes by Quantitative Urinalysis: Post Hoc Analysis of a Phase 3 Randomized Clinical Trial	4
Impact of Prenatal Cannabis Use Disorder on Perinatal Outcomes	4
National Provider Survey: Use of Naltrexone for Pregnant Individuals with Substance Use Disorders	4
Secondary Analysis to Advance Characterization of On-body Electrocardiographic Sensors in a Clinical Cocaine Self-administration Paradigm	4
The Associations of Kratom (Mitragynine), Opioids, Other Substances, and Sociodemographic Variables to Drug Intoxication–related Mortality	4
Impact of Nicotine Replacement Therapy Sampling on Cessation-Related Processes	3
Take-home Naloxone at Opioid Treatment Programs: A Lifesaver	3
Pregnancy and Pregnancy Outcomes in a National Population Cohort of Patients Treated for Substance Use Disorders	3
Harm Reduction Approach to Increasing Self-reported Safe Medication Storage Among Pregnant and Parenting People Receiving Opioid Use Disorder Treatment	3
Naltrexone in the Treatment of Ketamine Use Disorders: A Case Report and Literature Review	3
Supporting Patients With Stimulant Use Disorder During and After Hospitalization With a Mobile App-based Contingency Management Intervention: A Feasibility and Acceptability Study	3
Machine Learning–Driven Analysis of Individualized Treatment Effects Comparing Buprenorphine and Naltrexone in Opioid Use Disorder Relapse Prevention	3
Responses to Buprenorphine-associated Oral Diseases: The Critical Need for Mechanistic Understanding	3
A Case of Maternal and Neonatal Withdrawal After Exposure to Fentanyl Adulterated With Medetomidine	3
Hospital-initiated Extended-release Injectable Buprenorphine Using a Novel Reallocation Initiative From an Outpatient Addiction Medicine Clinic	3
Evaluating the Impact of Low Threshold Bridge Clinic Expansion on Equitable Access to Substance Use Disorder Treatment	3